FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022165098> ?p ?o ?g. }

• W2022165098 endingPage "304" @default.
• W2022165098 startingPage "294" @default.
• W2022165098 abstract "Gegen (root of Pueraria lobata) is used in traditional Chinese medicine for treatment of cardiovascular diseases. In this study, the relaxant actions of three of its isoflavonoids; puerarin, daidzein, and daidzin, were investigated on rat-isolated cerebral basilar artery. Rat basilar artery rings were precontracted with 100 nM U46619. Involvement of endothelium-dependent mechanisms was investigated by mechanical removal of the endothelium and inhibitors of nitric oxide synthase (NOS) and cyclooxygenase (COX) enzymes. Adenylyl cyclase- and guanylyl cyclase-dependent pathways were investigated using their respective inhibitors 9-(tetrahydro-2-furanyl)-9H-purine-6-amine (SQ22536) and 1H-[1,2,4]oxadiazolo [4,3-[alpha]]-quinoxalin-1-one (ODQ). K+ channels were investigated by pretreatment of the artery rings with various K+ channel inhibitors, and Ca2+ channels were investigated in artery rings incubated with Ca2+-free buffer and primed with 100 nM U46619 for 5 min prior to adding CaCl2 to elicit contraction. Puerarin, daidzein, and daidzin produced concentration-dependent relaxation of the artery rings with concentration that produced 50% inhibition (IC50) of 304 ± 49 μM, 20 ± 7 μM, and 140 ± 21 μM, respectively. Removal of the endothelium produced no change on their vasorelaxant responses except the maximum response (Imax) to puerarin was inhibited by 28%. The NOS inhibitor NG-nitro-l-arginine methyl ester (L-NAME; 100 μM) also produced 45% inhibition on the puerarin-induced vasorelaxant response, but not the COX inhibitor flurbiprofen (10 μM). SQ22536 (100 μM) and ODQ (100 μM) did not affect the vasodilator responses to puerarin, daidzein and daidzin, but glibenclamide (1 μM), tetraethylammonium (TEA, 100 mM) or a combination of K+ channel inhibitors (100 nM iberiotoxin + 1 mM 4-aminopyridine + 100 μM barium chloride + 1 μM glibenclamide + 100 mM TEA) reduced their Imax. The contractile response to CaCl2 was attenuated by 61% and 34% in the presence of daidzein and daidzin, respectively, whereas, puerarin did not significantly affect the contraction. The vasorelaxant action of daidzein and daidzin involved opening of K+ channels and inhibition of Ca2+ influx in the vascular smooth muscle cells. There is no evidence supporting involvement of endothelium-derived relaxing factors (EDRFs) in their actions. In contrast, puerarin produced vasodilatation via an endothelium-dependent mechanism involving nitric oxide production and an endothelium-independent pathway mediated by the opening of K+ channels. The cerebral vasodilator activities of all these three isoflavonoids may be beneficial to patients with obstructive cerebrovascular diseases." @default.
• W2022165098 created "2016-06-24" @default.
• W2022165098 creator A5001758405 @default.
• W2022165098 creator A5015038302 @default.
• W2022165098 creator A5015046013 @default.
• W2022165098 creator A5026957684 @default.
• W2022165098 creator A5041465938 @default.
• W2022165098 creator A5058499967 @default.
• W2022165098 creator A5067966617 @default.
• W2022165098 creator A5069173993 @default.
• W2022165098 creator A5073203715 @default.
• W2022165098 creator A5081004832 @default.
• W2022165098 creator A5085228464 @default.
• W2022165098 date "2012-01-01" @default.
• W2022165098 modified "2023-10-06" @default.
• W2022165098 title "Mechanisms of the cerebral vasodilator actions of isoflavonoids of Gegen on rat isolated basilar artery" @default.
• W2022165098 cites W1964578737 @default.
• W2022165098 cites W1967018905 @default.
• W2022165098 cites W1979212937 @default.
• W2022165098 cites W1987956016 @default.
• W2022165098 cites W1990293568 @default.
• W2022165098 cites W1992942274 @default.
• W2022165098 cites W1994484837 @default.
• W2022165098 cites W1997783547 @default.
• W2022165098 cites W2002294698 @default.
• W2022165098 cites W2002891558 @default.
• W2022165098 cites W2018578102 @default.
• W2022165098 cites W2023732561 @default.
• W2022165098 cites W2026379738 @default.
• W2022165098 cites W2039934535 @default.
• W2022165098 cites W2040133649 @default.
• W2022165098 cites W2042640287 @default.
• W2022165098 cites W2058683100 @default.
• W2022165098 cites W2063982292 @default.
• W2022165098 cites W2068871547 @default.
• W2022165098 cites W2071941255 @default.
• W2022165098 cites W2076107212 @default.
• W2022165098 cites W2076999434 @default.
• W2022165098 cites W2080970298 @default.
• W2022165098 cites W2087135491 @default.
• W2022165098 cites W2088309451 @default.
• W2022165098 cites W2093188103 @default.
• W2022165098 cites W2094303056 @default.
• W2022165098 cites W2095985419 @default.
• W2022165098 cites W2096430334 @default.
• W2022165098 cites W2122613613 @default.
• W2022165098 cites W2232892077 @default.
• W2022165098 doi "https://doi.org/10.1016/j.jep.2011.11.021" @default.
• W2022165098 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22120017" @default.
• W2022165098 hasPublicationYear "2012" @default.
• W2022165098 type Work @default.
• W2022165098 sameAs 2022165098 @default.
• W2022165098 citedByCount "30" @default.
• W2022165098 countsByYear W20221650982012 @default.
• W2022165098 countsByYear W20221650982013 @default.
• W2022165098 countsByYear W20221650982014 @default.
• W2022165098 countsByYear W20221650982015 @default.
• W2022165098 countsByYear W20221650982016 @default.
• W2022165098 countsByYear W20221650982017 @default.
• W2022165098 countsByYear W20221650982019 @default.
• W2022165098 countsByYear W20221650982020 @default.
• W2022165098 countsByYear W20221650982021 @default.
• W2022165098 countsByYear W20221650982022 @default.
• W2022165098 crossrefType "journal-article" @default.
• W2022165098 hasAuthorship W2022165098A5001758405 @default.
• W2022165098 hasAuthorship W2022165098A5015038302 @default.
• W2022165098 hasAuthorship W2022165098A5015046013 @default.
• W2022165098 hasAuthorship W2022165098A5026957684 @default.
• W2022165098 hasAuthorship W2022165098A5041465938 @default.
• W2022165098 hasAuthorship W2022165098A5058499967 @default.
• W2022165098 hasAuthorship W2022165098A5067966617 @default.
• W2022165098 hasAuthorship W2022165098A5069173993 @default.
• W2022165098 hasAuthorship W2022165098A5073203715 @default.
• W2022165098 hasAuthorship W2022165098A5081004832 @default.
• W2022165098 hasAuthorship W2022165098A5085228464 @default.
• W2022165098 hasConcept C120770815 @default.
• W2022165098 hasConcept C126322002 @default.
• W2022165098 hasConcept C134018914 @default.
• W2022165098 hasConcept C142724271 @default.
• W2022165098 hasConcept C185592680 @default.
• W2022165098 hasConcept C204787440 @default.
• W2022165098 hasConcept C2777452348 @default.
• W2022165098 hasConcept C2777622882 @default.
• W2022165098 hasConcept C2778298627 @default.
• W2022165098 hasConcept C2778356392 @default.
• W2022165098 hasConcept C2779768347 @default.
• W2022165098 hasConcept C2780955279 @default.
• W2022165098 hasConcept C2781012200 @default.
• W2022165098 hasConcept C519581460 @default.
• W2022165098 hasConcept C555293320 @default.
• W2022165098 hasConcept C71924100 @default.
• W2022165098 hasConcept C98274493 @default.
• W2022165098 hasConceptScore W2022165098C120770815 @default.
• W2022165098 hasConceptScore W2022165098C126322002 @default.
• W2022165098 hasConceptScore W2022165098C134018914 @default.
• W2022165098 hasConceptScore W2022165098C142724271 @default.
• W2022165098 hasConceptScore W2022165098C185592680 @default.
• W2022165098 hasConceptScore W2022165098C204787440 @default.

• next